Catalent, Inc.

Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the “Form 10-K”) by the prescribed filing due date of August 29, 2024 because the Company requires additional time to complete certain processes and closing procedures. The Company is working diligently and expects to file the Form 10-K on or before the expiration of the fifteen calendar day extension period provided in Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Based on currently available information and subject to the completion of the procedures described above, the Company does not expect any material change to the financial results to be included in the Form 10-K compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Current Report on Form 8-K filed on August 29, 2024

Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”) by the prescribed filing due date of February 9, 2024. The Company is working diligently and requires additional time to complete management’s continued evaluation of certain internal control matters and implementation of certain remediation efforts previously discussed in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023. The Company expects to file the Form 10-Q on or before the expiration of the five calendar day extension period provided in Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Based on currently available information and subject to the completion of the procedures described above, the Company does not expect any material change to the financial results to be included in the Form 10-Q compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Current Report on Form 8-K filed on February 9, 2024

Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “Form 10-Q”) by the prescribed filing due date of November 9, 2023 and does not expect to file the Form 10-Q on or before the expiration of the five calendar day extension period provided in Rule 12b-25 of the Securities Exchange Act of 1934, as amended. As previously reported in the Company’s Notification of Late Filing on Form 12b-25 filed on August 30, 2023 with the Securities and Exchange Commission (“SEC”), the Company was unable to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (“2023 Form 10-K”) within the prescribed period because it required additional time to complete its procedures related to management’s assessment of the effectiveness of its internal controls over financial reporting as of June 30, 2023 and other closing procedures. The Company continues to dedicate significant resources to the completion of such procedures for the fourth quarter of fiscal year 2023. The Company also requires additional time to complete its procedures related to management’s assessment of the measurement and timing of a non-cash goodwill impairment of approximately $700 million which relates primarily to acquisitions in the Company’s Consumer Health and Biomodalities reporting units in its Pharma and Consumer Health and Biologics segments, respectively, and other closing procedures. The Company is working diligently to complete the necessary work to file the 2023 Form 10-K, which is expected on or before November 27th, and currently expects to file the Form 10-Q promptly following the filing of the 2023 Form 10-K

Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “Form 10-K”) by the prescribed filing due date of August 29, 2023. The Company requires additional time to complete its procedures related to management’s assessment of the effectiveness of its internal controls over financial reporting as of June 30, 2023 and other closing procedures. Based on currently available information and subject to the completion of the preparation of the Company’s financial statements and assessment of the Company’s internal controls over financial reporting and completion of the audits thereof, the Company does not expect any material change to the financial results included in the Form 10-K compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed on August 29, 2023 (the “Earnings Release”). As noted above in Part II of this form, the Company believes that the Form 10-K will be filed within the extension period provided by Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended, but can provide no assurance that it will be able to file by such time

Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “Form 10-Q”) by the prescribed filing due date of May 10, 2023, for the reasons described below. As the Company disclosed in its press release dated May 8, 2023, in the course of finalizing its financial statements for the third fiscal quarter ended March 31, 2023, the Company identified certain accounting adjustments related to its operations in Bloomington, Indiana. These adjustments stem from revenue recognized under certain contractual arrangements that the Company has since determined were incorrectly recognized as of the fourth fiscal quarter ended June 30, 2022 and the first fiscal quarter ended September 30, 2022. The Company is still evaluating the accounting associated with these errors and their effect on previously issued financial statements included in its Annual Report on Form 10-K for the year ended June 30, 2022 and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022. The Company is also assessing the related effects of the errors on the Company’s evaluation of internal control over financial reporting and its disclosure controls and procedures. In addition, the Company is finalizing its evaluation of a goodwill impairment in its consumer health business. As a result of the foregoing, the Company requires additional time to complete its preparation and review of its financial statements and other disclosures in the Form 10-Q, and to complete its quarterly closing processes and procedures. The Company, a large accelerated filer, is working diligently to complete the necessary work to file the Form 10-Q with the Securities and Exchange Commission as soon as practicable